Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
- PMID: 21121873
- DOI: 10.1517/13543784.2011.542147
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
Abstract
Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies.
Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibody-drug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials.
What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations.
Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30(+) lymphomas.
Similar articles
-
Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Drugs Today (Barc). 2012. PMID: 22536568 Review.
-
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30. Oncologist. 2016. PMID: 26621039 Free PMC article.
-
Brentuximab vedotin for the treatment of CD30+ lymphomas.Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Immunotherapy. 2011. PMID: 21463188 Review.
-
Brentuximab vedotin in anaplastic large cell lymphoma.Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27. Expert Opin Biol Ther. 2012. PMID: 22449148
-
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.Anticancer Agents Med Chem. 2017;17(7):886-895. doi: 10.2174/1871520616666160902100506. Anticancer Agents Med Chem. 2017. PMID: 27592544 Review.
Cited by
-
Marine anticancer drugs and their relevant targets: a treasure from the ocean.Daru. 2019 Jun;27(1):491-515. doi: 10.1007/s40199-019-00273-4. Epub 2019 Jun 5. Daru. 2019. PMID: 31165439 Free PMC article. Review.
-
Trial Watch: Monoclonal antibodies in cancer therapy.Oncoimmunology. 2012 Jan 1;1(1):28-37. doi: 10.4161/onci.1.1.17938. Oncoimmunology. 2012. PMID: 22720209 Free PMC article.
-
TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.J Immunol. 2011 Oct 15;187(8):4040-50. doi: 10.4049/jimmunol.1100532. Epub 2011 Sep 9. J Immunol. 2011. PMID: 21908732 Free PMC article.
-
Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.Theranostics. 2020 Jan 1;10(2):938-955. doi: 10.7150/thno.37443. eCollection 2020. Theranostics. 2020. PMID: 31903161 Free PMC article. Review.
-
Next generation of antibody therapy for cancer.Chin J Cancer. 2011 May;30(5):293-302. doi: 10.5732/cjc.011.10123. Chin J Cancer. 2011. PMID: 21527062 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
